Abstract: A method of manufacturing an implant is disclosed. The method includes preparing a wax template assembly based upon anatomical characteristics of an implantation site. Post formation of the template assembly, a lamination layer is provided over the template assembly resulting in a laminated template assembly. The lamination layer is composed of at least one polymer dissolved in one or more solvents. One or more coating layers of a pre-defined coating material are provided over the laminated template assembly to prepare a mold. The mold may then be sand-rained to form a sand coated mold. The sand coated mold may be de-waxed and baked for melting out the template assembly to form a de-waxed mold. A casting material is then poured over the de-waxed mold to form a casted mold which is cooled and solidified to form a casted implant which is further heat treated and finished to form the implant.

Abstract: A stent system is disclosed. The stent system includes a balloon catheter having a balloon with a proximal zone, a transition zone and a distal zone including progressively decreasing diameters respectively. The stent of a pre-defined length includes a main branch segment, a transition segment and a side branch segment. The stent includes an expanded state and a crimped state. The stent is mounted over the balloon in the crimped state such that the main branch segment is mounted over the proximal zone, the transition segment is mounted over the transition zone and the side branch segment is mounted over the distal zone. In expanded state, the main branch segment, the transition segment and the side branch segment of the stent correspond to the respective zones of the balloon. The transition segment includes plural rows of elongated members connected to each other.

Abstract: There is disclosed a process for treatment to avert enzymatic degradation and tissue degeneration of bovine pericardium tissue, used for making bioprosthesis for implant application, comprising the steps of collecting and harvesting raw bovine pericardial tissue; chemically cross-linking the rinsed tissue to generate fixed tissue; laser cutting said fixed tissue to produce tissue leaflet; chemically treating said tissue leaflet with AAS; chemically sterilising and storing the fixed bovine pericardium tissue to maintain the structural integrity and characteristics; and wherein all the above steps are carried out in a low-oxygen and controlled temperature environment.

Abstract: A prosthetic heart valve assembly is disclosed. The said assembly includes a prosthetic heart valve (10). The said valve (10) is mounted over a balloon (5) for deployment at a target location. The dimensions of the said valve (10) mimic the anatomy of a native heart valve. The delivery catheter (100) is used for deployment of the prosthetic heart valve (10). The delivery catheter (100) includes a handle (11), a multi-layered outer shaft (1) and/or an inner shaft (3) including an inner second end (3b). A support tube (7) is disposed on top of the inner second end (3b) and includes one or more holes (7a) for passing an inflation fluid and is provided with the balloon (5) on its outer surface. One or stoppers (9) are provided on the support tube (7) and within the balloon (5) and include a first portion (C) and a second portion (D).

Abstract: A prosthetic valve has fluoroscopic properties for precise placement of the prosthetic valve in a human stenosed aortic orifice. The prosthetic valve comprises a support frame having a distal and a proximal end, and three adjacently placed rows of hexagonal cells (namely an upper, middle and a lower row). The upper row occupies 50-55% of total length of the support frame. The support frame of the prosthetic valve under fluoroscopy comprises a plurality of light bands and dark bands alternating with each other along the length of the support frame. Further, a second dark band from the distal end of the support frame is bisected by aortic annular plane on placement in orthotopic position of a human stenosed aortic orifice. The prosthetic valve offers advantages such as minimal protrusion in left ventricle and minimal obstruction of prosthetic valve to ostia of coronary arteries.

Abstract: A vascular closure system is configured to seal an incision in a vessel of the patient's body. The system includes a slider that is moved from an initial position to a deployed position (that is, towards the puncture of the patient body), until the proximal end of the slider exposes a reference marker on an inner tube. This confirms the deployment of the closure element and completely expands or opens or pivots the closure element in the blood vessel.

Abstract: An inserter is provided which includes a handle having an upper cover and a bottom cover, the upper cover having a longitudinal opening, a proximal end and a distal end; a mounting member extending from an inner surface of the bottom cover of the handle, the mounting member having a through-hole; an inner tube having a proximal end and a distal end, the proximal end of the inner tube attached to the mounting member; an insertion tube movably coupled to the inner tube with a longitudinal axis essentially parallel to a longitudinal axis of the inner tube; a switch coupled to a proximal end of the insertion tube and arranged in the opening; and a string having a proximal end removably coupled near the proximal end of the opening, a distal end of the string coupled to a device to be inserted inside a human anatomy.

Abstract: This invention discloses a process for preparation of a balloon expandable biodegradable polymer stent with thin struts (strut thickness 130 ?m or less, preferably 100-110 ?m) with high fatigue and radial strength. The invention discloses a process for the preparation of a biodegradable polymer stent which involves radially deforming the biodegradable polymer tube by applying pressure to it with an inert gas at a predefined temperature in multiple stages with each successive stage having a pressure higher than the pressure applied in a previous stage. The process further involves maintaining the predefined temperature and pressure conditions of each stage for a specified time period after application of the pressure.

Abstract: This invention discloses a process for preparation of a balloon expandable biodegradable polymer stent with thin struts (strut thickness 130 ?m or less, preferably 100-110 ?m) with high fatigue and radial strength. The invention discloses a process for the preparation of a biodegradable polymer stent which involves deforming an extruded biodegradable polymer tube axially at a first predefined temperature by applying an axial force for a first predefined time interval. The process further includes radially expanding the axially stretched tube at a second predefined temperature by pressurizing the tube with an inert gas in one or more stages, the pressure applied in each successive stage being higher than the pressure applied in a previous stage.

Abstract: The invention discloses a process for the preparation of a biodegradable stent which involves deforming an extruded biodegradable polymer tube axially at a first predefined temperature by applying an axial force for a first predefined time interval. The process is followed by radially expanding the axially stretched tube at a second predefined temperature by pressurizing the tube with an inert gas in one or more stages, the pressure applied in each successive stage being higher than the pressure applied in a previous stage. The process further comprises laser cutting a specific pattern of scaffold structure on the expanded tube and then crimping the laser cut stent on the balloon of delivery catheter in a sterile environment in multiple stages.

Abstract: This invention discloses method of manufacture of balloon expandable stent made from bioabsorbable polymer with thin struts (strut thickness 130 ?m or less, preferably 100-110 ?m) with high fatigue and radial strength. The invention further discloses balloon expandable stent made from bioabsorbable polymer with thin struts (strut thickness 130 ?m or less, preferably 100-110 ?m) with high fatigue and radial strength.

Abstract: A prosthetic valve has fluoroscopic properties for precise placement of the prosthetic valve in a human stenosed aortic orifice. The prosthetic valve comprises a support frame having a distal and a proximal end, and three adjacently placed rows of hexagonal cells (namely an upper, middle and a lower row). The upper row occupies 50-55% of total length of the support frame. The support frame of the prosthetic valve under fluoroscopy comprises a plurality of light bands and dark bands alternating with each other along the length of the support frame. Further, a second dark band from the distal end of the support frame is bisected by aortic annular plane on placement in orthotopic position of a human stenosed aortic orifice. The prosthetic valve offers advantages such as minimal protrusion in left ventricle and minimal obstruction of prosthetic valve to ostia of coronary arteries.

Abstract: A suture tray having an upper component with a top surface and a bottom surface is disclosed. The tray also includes a plurality of flexible members integrally coupled to the upper component such that the flexible members have a clearance for assisting easy lift-press mechanism and a lower component having an outer peripheral wall and inner peripheral wall. The outer and inner peripheral wall mate with the upper component to form a winding channel. The tray also includes a secondary female locking member integrally coupled to the inner peripheral wall, the secondary female locking member mates with a secondary male locking member integrally formed on the upper component to additionally lock the assembly.

Abstract: An inserter is provided which includes a handle having an upper cover and a bottom cover, the upper cover having a longitudinal opening, a proximal end and a distal end; a mounting member extending from an inner surface of the bottom cover of the handle, the mounting member having a through-hole; an inner tube having a proximal end and a distal end, the proximal end of the inner tube attached to the mounting member; an insertion tube movably coupled to the inner tube with a longitudinal axis essentially parallel to a longitudinal axis of the inner tube; a switch coupled to a proximal end of the insertion tube and arranged in the opening; and a string having a proximal end removably coupled near the proximal end of the opening, a distal end of the string coupled to a device to be inserted inside a human anatomy.

Abstract: A vascular closure system is configured to seal an incision in a vessel of the patient's body. The system includes a slider that is moved from an initial position to a deployed position (that is, towards the puncture of the patient body), until the proximal end of the slider exposes a reference marker on an inner tube. This confirms the deployment of the closure element and completely expands or opens or pivots the closure element in the blood vessel.

Abstract: This invention discloses a process for preparation of a balloon expandable biodegradable polymer stent with thin struts (strut thickness 130 ?m or less, preferably 100-110 ?m) with high fatigue and radial strength. The invention discloses a process for the preparation of a biodegradable polymer stent which involves radially deforming the biodegradable polymer tube by applying pressure to it with an inert gas at a predefined temperature in multiple stages with each successive stage having a pressure higher than the pressure applied in a previous stage. The process further involves maintaining the predefined temperature and pressure conditions of each stage for a specified time period after application of the pressure.

Abstract: The invention discloses a process for the preparation of a biodegradable stent which involves deforming an extruded biodegradable polymer tube axially at a first predefined temperature by applying an axial force for a first predefined time interval. The process is followed by radially expanding the axially stretched tube at a second predefined temperature by pressurizing the tube with an inert gas in one or more stages, the pressure applied in each successive stage being higher than the pressure applied in a previous stage. The process further comprises laser cutting a specific pattern of scaffold structure on the expanded tube and then crimping the laser cut stent on the balloon of delivery catheter in a sterile environment in multiple stages.

Abstract: This invention discloses a process for preparation of a balloon expandable biodegradable polymer stent with thin struts (strut thickness 130 ?m or less, preferably 100-110 ?m) with high fatigue and radial strength. The invention discloses a process for the preparation of a biodegradable polymer stent which involves deforming an extruded biodegradable polymer tube axially at a first predefined temperature by applying an axial force for a first predefined time interval. The process further includes radially expanding the axially stretched tube at a second predefined temperature by pressurizing the tube with an inert gas in one or more stages, the pressure applied in each successive stage being higher than the pressure applied in a previous stage.

Abstract: This invention discloses method of manufacture of balloon expandable stent made from bioabsorbable polymer with thin struts (strut thickness 130 ?m or less, preferably 100-110 ?m) with high fatigue and radial strength. The invention further discloses balloon expandable stent made from bioabsorbable polymer with thin struts (strut thickness 130 ?m or less, preferably 100-110 ?m) with high fatigue and radial strength.

Abstract: The invention discloses novel 42-0-(heteroalkoxyalkyl) rapamycin compounds of formula (1) and process for preparation thereof. These compounds are useful in the treatment of hyperproliferative vascular diseases such as restenosis and atherosclerosis Wherein, R denotes 3, 4 and 5 membered 3-hydroxy heteroalkoxyalkyl compounds selected from Tetrahydrofuran-3-ol, Oxetan-3-ol, Tetrahydropyran-3-ol, Tetrahydro-4- methyl furan-3-ol, Tetrahydro-2,5,5-trimethyl furan-3-ol, Tetrahydro-2,5-diethyl-2-methyl furan-3-ol, Tetrahydro-6-methoxy-2-methyl 2H-Pyran-3-ol and Tetrahydro-2,2-dimethyl-6-phenyl 2H-Pyran-3-ol.